The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic Mice

Linlin Bao†,[1], Wei Deng†,[1], Baoying Huang†,[2], Hong Gao†,[1], Lili Ren[3], Qiang Wei[1], Pin Yu[1], Yanfeng Xu[1], Jiangning Liu[1], Feifei Qi[1], Yajin Qu[1], Wenling Wang[2], Fengdi Li[1], Qi Lv[1], Jing Xue[1], Shuran Gong[1], Mingya Liu[1], Guanpeng Wang[1], Shunyi Wang[1], Linna Zhao[1], Peipei Liu[2], Li Zhao[2], Fei Ye[2], Huijuan Wang[2], Weimin Zhou[2], Na Zhu[2], Wei Zhen[2], Haisheng Yu[1], Xiaojuan Zhang[1], Zhiqi Song[1], Li Guo[3], Lan Chen[3], Conghui Wang[3], Ying Wang[3], Xinming Wang[3], Yan Xiao[3], Qiangming Sun[4], Hongqi Liu[4], Fanli Zhu[4], Chunxia Ma[4], Lingmei Yan[4], Mengli Yang[4], Jun Han[2], Wenbo Xu[2], Wenjie Tan[2], Xiaozhong Peng[4], Qi Jin[3], Guizhen Wu*,[2], Chuan Qin*,[1]

[1] Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.

[2] MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.

[3] Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, China.

[4] Institute of Medical Biology, Chinese Academy of Medical Sciences, Beijing, China.

†These authors contributed equally to this work.

*Correspondence should be addressed to Chuan Qin, Email: qinchuan@pumc.edu.cn, or Guizhen Wu, Email: wugz@ivdc.chinacdc.cn.

Abstract

2019-nCoV caused pneumonia cases in China has become a public health emergency of

international concern (PHEIC). The first priority for prevention and treatment of the

disease is to find the pathogenicity of 2019-nCoV *in vivo*. Weight loss and virus

replication were detected in infected-hACE2 mice. The typical histopathology was

interstitial pneumonia with significant inflammatory cells infiltration around the

bronchioles and blood vessels, and viral antigens were observed in bronchial epithelial

cells and alveolar epithelial cells. The phenomenon was not found in wild type mice

infected with 2019-nCoV and the mock-infected hACE2 mice. The pathogenicity of

2019-nCoV in hACE2 mice was clarified and the Koch's postulates was fulfilled as well,

and the model may facilitate the development of therapeutics and vaccines against 2019-

nCoV.

In late December of 2019, a cluster of severe pneumonia cases caused by 2019 novel coronavirus (2019-nCoV), linked to a seafood market in which exotic animals were also sold and consumed, were identified and reported from Wuhan City, Hubei Province, China[1,2]. The number of infections has since soared, with almost 10,000 cases reported and over 200 deaths as of January 31, 2020 in China[3], and imported cases from travelers of mainland China in several other countries. It is critical to find the pathogenicity and biology of the virus for prevention and treatment of the disease.

Because 2019-nCoV was highly homologous with Severe acute respiratory syndrome coronavirus (SARS-CoV), human Angiotensin-converting enzyme 2 (hACE2), which was the entry receptor of SARS-CoV, was also considered to have a high binding ability with the 2019-nCoV by molecular biological analysis[4,5]. Therefore, we used the hACE2 transgenic and wild type mice infected with or without 2019-nCoV infection to study the pathogenicity of the virus. Specific pathogen-free, 6-11-month-old, male and female hACE2 mice and wild type mice (n=7) were inoculated intranasally with 2019-nCoV stock virus at a dosage of 10^5 TCID$_{50}$ per mouse, and the mock-infected hACE2 mice (n=3) were used as control. Weight loss of up to 5% was observed for 10 dpi only in the 2019-nCoV-infected hACE2 mice (Figure 1a), and other clinical symptoms were not observed. Major organs were harvested at 3 dpi and 5 dpi to assess for biodistribution of 2019-nCoV in infected hACE2 mice. Viral RNA was positive by RT-PCR (Figure 1b) and identified by sequencing only in the lung of infected-hACE2 mice at 3 dpi and 5 dpi. Meanwhile, the virus was successfully isolated by Vero cells culture (Figure 1d) and observed by an electron microscope (Figure 1e). However, the virus was not found in the PBS-infected hACE2 mice or infected-wild type mice (data not shown).

The typical pneumonia was demonstrated as bilateral ground-glass opacity and

subsegmental areas of consolidation by image in patient[6], but no histopathological results

were reported until now. The major organs of mice were examined by histopathology and

immunofluorescence. Compared to PBS-infected hACE2 mice or 2019-nCoV-infected-

wild type mice (Figure 2a and b), focal lesions were observed in the dorsal of the right

middle lobe in 2019-nCoV-infected hACE2 mice (Figure 2c). Consistently, lung tissues

from 2019-nCoV-infected hACE2 mice had multifocally mild or moderate pneumonia

with interstitial hyperplasia. And significant inflammatory cells infiltration around the

bronchioles and blood vessels (Figure 2f) were found. The alveolar interstitium is also

expanded with inflammatory cells, and the alveolar lumen contains cell debris mixed

with leukocytes. Bronchial epithelial cells showed swelling, degeneration, and some of

them dissolved and necrotic foci (Figure 2g, h and i). Meanwhile, 2019-nCoV antigens

were observed in the bronchial epithelial cells (Figures 3h and i) and alveolar epithelial

cells (Figures 3n, o, p and q) of lungs in 2019-nCoV-infected hACE2 mice. In addition,

the co-localization of 2019-nCoV S protein and hACE2 receptor was demonstrated in

alveolar epithelial cells of infected-hACE2 mice by immunofluorescence (Figures 3n, o,

p and q). The phenomenon was not found in the PBS-infected hACE2 mice (Figures 3k, i

and m) or infected-wild type mice (data not shown).

The speed of geographical spread of severe viral pneumonia disease caused by

2019-nCoV has been declared as public health emergency of international concern

(PHEIC), with cases reported on multiple continents only weeks after the disease was

first reported[7]. Although it has been determined by bioinformatics that the pathogen of

this epidemic is a novel coronavirus, it is necessary to be confirmed by animal

experiments following Koch's principles. After experimental infection of transgenic

hACE2 mice with one of the earliest known isolates of 2019-nCoV, the mice lost weight

and showed interstitial pneumonia, which are comparable with initial clinical reports of

pneumonia caused by 2019-nCoV[6]. In addition, the 2019-nCoV S protein and hACE2

receptor were found to co-localize in alveolar epithelial cells, supporting that the 2019-

nCoV, similar to SARS-CoV, also utilizes the hACE2 as a receptor for entry[4]. Therefore,

the present study clarified the pathogenicity of 2019-nCoV in hACE2 mice and fulfills

the Koch's postulates as well, and the model may facilitate the development of drugs and

vaccines against 2019-nCoV.

Materials and methods

Ethics statement

Murine studies were performed in an animal biosafety level 3 (ABSL3) facility using

HEPA-filtered isolators. All procedures in this study involving animals were reviewed

and approved by the Institutional Animal Care and Use Committee of the Institute of

Laboratory Animal Science, Peking Union Medical College (BLL20001).

Viruses and cells

The 2019-nCoV (strain HB-01) was kindly provided by Professor Wenjie Tan[1], from the

China Centers for Disease Control and Prevention (China CDC). The complete genome

for this 2019-nCoV was submitted to GISAID (BetaCoV/Wuhan/IVDC-HB-

01/2020|EPI_ISL_402119), and deposited in the China National Microbiological Data

Center (accession number NMDC10013001 and genome accession numbers

MDC60013002-01). Seed 2019-nCoV stocks and virus isolation studies were performed

in Vero cells, which are maintained in Dulbecco's modified Eagle's medium (DMEM,

Invitrogen, Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS), 100 IU/ml

penicillin, and 100 µg/ml streptomycin, and incubated at 37°C, 5% CO_2. Titers for 2019-

nCoV were determined using a standard 50% tissue culture infection dose ($TCID_{50}$) assay.

Animal experiments

For the animal experiments, specific pathogen-free, 6-11-month-old, male and female

transgenic hACE2 mice were obtained from the Institute of Laboratory Animal Science,

Peking Union Medical College, China. Transgenic mice were generated by

microinjection of the mice ACE2 promoter driving the human ACE2 coding sequence

into Institute of Cancer Research (ICR) or C57BL/6J mice[8]; the presence of human

ACE2 in the mice used for these experiments was confirmed by PCR (data not shown).

The hACE2 mice (n=7) or ICR mice (n=5) were respectively inoculated intranasally with

2019-nCoV stock virus at a dosage of 10^5 $TCID_{50}$ per mouse. As a control, hACE2 mice

(n=3) were mock-infected with an equivalent challenge volume of PBS. PBS- and 2019-

nCoV-infected animals were continuously observed daily to record body weights, clinical

symptoms, decreased responsiveness to external stimuli and death. Two mice from the

2019-nCoV-infected group were dissected at 3 days post-infection (dpi) and at 5 dpi to

collect trachea, lung, kidney, brain, spleen, and liver tissues for the determination of viral

load after 2019-nCoV infection. One mouse from the PBS-infected group was dissected

at 3 dpi as a control. One mouse from the ICR mice group inoculated with 2019-nCoV

was dissected at 3 dpi as the receptor control.

Preparation of Homogenate Supernatant

Tissues homogenates were prepared by homogenizing perfused whole tissue using an electric homogenizer for 2 min 30 s in 1 ml of DMEM. The homogenates were centrifuged at 3,000 rpm for 10 min at 4°C. The supernatant was collected and stored at −80°C for viral isolation and viral load detection.

RNA extraction and RT-PCR

Total RNA was extracted from organs using the RNeasy Mini Kit (Qiagen, Hilden, Germany), and reverse transcription was performed using the PrimerScript RT Reagent Kit (TaKaRa, Japan) following manufacturer instructions. RT-PCR reactions were performed using the PowerUp SYBG Green Master Mix Kit (Applied Biosystems, USA), in which samples were processed in duplicate using the following cycling protocol: 50°C for 2 min, 95°C for 2 min, followed by 40 cycles at 95°C for 15 s and 60°C for 30 s, and then 95°C for 15 s, 60°C for 1 min, 95°C for 45 s. The primer sequences used for RT-PCR are targeted against the envelope (E) gene of 2019-nCoV and are as follows: Forward: 5'-TCGTTTCGGAAGAGACAGGT-3', Reverse: 5'-GCGCAGTAAGGATGGCTAGT-3'.

Laboratory preparation of the antibody of 2019-nCoV Spike-1 (S1) protein

Mice were immunized with purified 2019-nCoV S1 protein (Sino biological) and splenocytes of hyper immunized mice were fused with myeloma cells. Positive clones were selected by ELISA using 2019-nCoV S1 protein (Supplementary Figure 1). The cell

supernatant of 7D2 clone, binding to 2019-nCoV S1 protein, was collected for

immunofluorescence analysis.

Hematoxylin and Eosin Staining

For each mouse, the whole left lung was embedded in Cryo-Gel for histological

examination by frozen section method. The lung tissue sections (10 um) were fixed in

100% acetone for 15 minutes and stained with Hematoxylin and Eosin (H&E). The

histopathology of the lung tissue was observed by light microscopy.

Immunofluorescence and confocal microscopy

For viruses and ACE2 receptor localization analysis, the lung tissue sections (10 um)

were washed twice with PBS, fixed by Immunol Staining Fix Solution (P0098), blocked

1 hour at room temperature by Immunol Staining Blocking Buffer (P0102) and then

incubated overnight at 4°C with the appropriate primary and secondary antibodies. The

nuclei were stained with DAPI. First, anti-2019-nCoV S protein (laboratory preparation)

and sera of patient in convalescent phase were used to test the 2019-nCoV, respectively.

Secondly, for analysis the relationship between 2019-nCoV and ACE2 receptor, anti-

2019-nCoV S protein (mouse monoclonal 7D2, laboratory preparation, 1:200) and anti-

hACE2 antibody (rabbit polyclonal, ab15348, Abcam1:200) were used. The sections was

washed with PBS and incubated with secondary antibodies conjugated with FITC (goat

anti-human, ab6854, Abcam, 1:200), TRITC (goat anti rabbit, ZF-0317, Beijing ZSGB

Biotechnology, 1:200), or FITC (goat anti-mouse, ZF-0312, Beijing ZSGB

Biotechnology, 1:200), respectively, dried at room temperature and observed via
fluorescence microscopy.

Statistical analysis

All data were analyzed with GraphPad Prism 6.0 software. Statistically significant
differences between the virus HB-01-infected hACE2 mice and other mice with or
without HB-01 infection were determined using Welch's t-test. The level of statistical
significance is designated as *p<0.05, **p<0.01 or [#]p<0.05, [##]p<0.01.

Acknowledgement

We thank Hongkui Deng, Xiuhong Yang and Lianfeng Zhang for providing the hACE2
mice as a gift. We also thank Gary Wong for helping us proofread the language. This
work was supported by the National Research and Development Project of China (Grant
No. 2020YFC0841100), National Key Research and Development Project of China
(Grant No. 2016YFD0500304), CAMS initiative for Innovative Medicine of China
(Grant No. 2016-I2M-2-006), National Mega projects of China for Major Infectious
Diseases (2017ZX10304402).

References
1. Zhu N, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med.*
2020 Jan 24. doi: 10.1056/NEJMoa2001017.
2. Ren LL, et al. Identification of a novel coronavirus causing severe pneumonia in human: a
descriptive study. *Chin Med J (Engl).* 2020 Jan 30. doi: 10.1097/CM9.0000000000000722.

3. China National Health Commission. Update on the novel coronavirus pneumonia outbreak (Jan 24,

2020). Beijing: China National Health Commission, 2020.

http://www.nhc.gov.cn/yjb/s7860/202002/84faf71e096446fdb1ae44939ba5c528.shtml.

4. Xintian Xu, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and

modeling of its spike protein for risk of human transmission. Science China.2020.1.

5. Kuba K, et al. A crucial role of angiotensin converting enzyme 2 (hACE2) in SARS coronavirus-

induced lung injury. Nat Med. 2005 Aug;11(8):875-9. doi: 10.1038/nm1267.

6. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Lancet. 2020 Jan 24. pii: S0140-6736(20)30183-5. doi: 10.1016/S0140-6736(20)30183-5.

7. Chan JF, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus

indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Jan 24. pii: S0140-

6736(20)30154-9. doi: 10.1016/S0140-6736(20)30154-9.

8. Yang XH, et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for

SARS coronavirus infection. Comp Med. 2007 Oct;57(5):450-9.

Figure 1. Weight loss and virus detection in hACE2 mice post infection with 2019-nCoV. Two groups of mice were experimentally challenged intranasally with a dose of 10^5 TCID$_{50}$ 2019-nCoV, and the PBS-infected hACE2 mice were used as control. WT mice were inoculated with 2019-nCoV as receptor control. And then the weight loss was recorded over 10 days (a). Mice were sacrificed and their major organs harvested for viral load and virus isolation at 3 and 5 dpi, the distribution of 2019-nCoV in various organs of infected hACE2 mice was detected by RT-PCR and the results of 3 dpi was representatively shown (b) (line 1: positive control, line2: negative control, line 3-10: trachea, lung, heart, spleen, intestine, liver, kidney and brain in turn). (c) Live virus could not be isolated from the lungs of infected-WT mice on Vero cells, but (d) cytopathic effects were observed from Vero cells infected with homogenate from the lungs of infected-hACE2 mice. Electron microscope pictures of 2019-nCoV from infected-hACE2 mice lung tissue culture homogenate at 3 dpi (e). Significant differences are indicated with different asterisks (Welch's t-test, ACE2-HB-01 vs ACE2-PBS, *$p<0.05$, **$p<0.01$; ACE2-HB-01 vs WT-HB-01, $^{\#}p<0.05$, $^{\#\#}p<0.01$).

Figure 2. Gross pathology and histopathology of lungs of 2019-nCoV-infected hACE2 mice. Gross pathology of lungs from infected-WT mice (a), PBS-infected hACE2 mice (b) and 2019-nCoV-infected hACE2 mice (c) at 3 dpi. (d-i) Histological examination of lungs of infected-WT mice (d), PBS-infected hACE2 mice (e), and 2019-nCoV-infected hACE2 mice (f-i). Histopathological examination of bronchioles and blood vessels (f) and alveolar interstitum (g-i) from infected-hACE2 mice. Yellow bar = 200 μm, Black bar = 100 μm, Red bar = 50 μm.

Figure 3. Immunofluorescence analysis of viral antigens in lungs of 2019-nCoV-infected hACE2 mice. (a-i): Fluorescence of sections of mice lungs after incubation with DAPI or antisera of 2019-nCoV-convalescent patients respectively. The lung sections of infected-WT mice (a-c), PBS-infected hACE2 mice (d-f) and infected-hACE2 mice (g-i). Green arrows indicate presence of 2019-nCoV in the alveolar epithelial cells. (j-q): Co-localization of 2019-nCoV S protein and hACE2 receptor in hACE2 mouse lungs, the sections were incubated with DAPI, a polyclonal antibody against 2019-nCoV S protein

or human ACE2 protein respectively. The lung sections of PBS-infected hACE2 mice (j-

m). The lung sections of infected-hACE2 mice (n-q). The white arrows showed the viral

S protein (o) and hACE2 (p) respectively, the yellow arrows showed the merge of viral S

protein and hACE2 (q).

Supplementary Figure 1. Identification of 7D2 antibody against 2019-nCoV S1
protein. The plate coated by 0.2 ug 2019-nCoV S1 protein was incubated with 7D2
antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-
mouse secondary antibody. The titer of antibody was determined using enzyme-linked
immunosorbent assay (ELISA) assay. Significant differences are indicated with an
asterisk (unpaired t-test, *p<0.05*).

257